Edwards Lifesciences has a transcatheter mitral valve replacement program in the works with it Fortis valve.
It has endured bumps on the road with a temporarily paused feasibility trial but recently received FDA approval to go ahead, said Michael Mussallem, CEO of Edwards Lifesciences, in the company’s second-quarter earnings call on Tuesday. By Mussallem’s own admission, he is happy with the progress of the company’s internal TMVR program.
Yet, earlier this month, Edwards announced it will pay up to $400 million to buy a rival in that arena - CardiAQ Valve Technologies. Why? It’s a question that came up from analysts in the company’s earnings call.
Hey, check out all the engineering jobs. Post your resume today!
